Daily FNArena News - Small Caps

Following a meeting with management Moelis remains attracted to Thorn Group, seeing value at current levels given the defensive nature of the group’s earnings.

Growth potential as IT junior NEXTDC rolls out a national data centre offering sees Moelis rate the stock as a Buy.

An unusual business model and a solid growth outlook are a positive combination for GR Engineering, reports Macquarie.

Labour hire and replacement group Humanis is delivering earnings growth both organically and via acquisitions and this attractive growth outlook sees Moelis rate the stock as a Buy.

A history of solid earnings growth and rising dividends and expectations of more of the same sees DJ Carmichael initiate coverage on Lycopodium with a Buy rating.

Phosphagenics continues to develop its TPM drug patch delivery technology and Bell Potter sees this as a key advantage for the company in breaking into sizable markets.

REVA Medical has seen the timeline for starting clinical trials of its bioresorbable stent slip but Bell Potter says any associated share price weakness would be a buying opportunity.

A profit result better than guidance and expectations of further growth lead Microequities to retain a Strong Buy rating on IT junior BigAir.

A well received full year profit result and a solid growth outlook suggest value in Tox Free Solutions at current levels.

While full year earnings met expectations a tough operating environment means limited shorter-term earnings growth for Peet, but brokers continue to see value.